Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.56 USD
+0.06 (2.40%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $2.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
Company Summary
Los Angeles, CA-based Puma Biotechnology, Inc. is a cancer biotech whose only marketed product is Nerlynx (neratinib). The drug is currently approved in the United States for two indications: the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer following adjuvant Herceptin-based therapy and for use in combination with Roche’s Xeloda for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Nerlynx recorded sales worth $203.1 million in 2023, ...
Company Summary
Los Angeles, CA-based Puma Biotechnology, Inc. is a cancer biotech whose only marketed product is Nerlynx (neratinib). The drug is currently approved in the United States for two indications: the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer following adjuvant Herceptin-based therapy and for use in combination with Roche’s Xeloda for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Nerlynx recorded sales worth $203.1 million in 2023, up 1.6% year over year.
Puma Biotechnology markets Nerlynx in the United States and has several sub-licenses in various regions outside the United States to commercialize Nerlynx in some international markets.
In September 2022, Puma Biotechnology in-licensed global development and commercialization rights to alisertib, an aurora kinase A inhibitor, from Japan’s Takeda.
Puma Biotechnology plans to develop alisertib for the treatment of various types of cancer indications, including hormone receptor-positive breast cancer as well as small-cell lung cancer (SCLC).
If alisertib is successfully developed for the mentioned indications, it could enhance Puma Biotechnology’s position in the target market for anti-cancer drugs.
The company recorded total revenues of $235.6 million for 2023 compared with $228 million reported in 2022.
General Information
Puma Biotechnology, Inc
10880 WILSHIRE BOULEVARD SUITE 2150
LOS ANGELES, CA 90024
Phone: 424-248-6500
Fax: 424-248-6501
Web: http://www.pumabiotechnology.com
Email: ir@pumabiotechnology.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.35 |
Current Year EPS Consensus Estimate | 0.43 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 2.50 |
52 Week High | 7.73 |
52 Week Low | 2.13 |
Beta | 1.09 |
20 Day Moving Average | 311,147.31 |
Target Price Consensus | 5.50 |
4 Week | -7.41 |
12 Week | -20.38 |
YTD | -42.26 |
4 Week | -7.36 |
12 Week | -22.37 |
YTD | -50.98 |
Shares Outstanding (millions) | 49.05 |
Market Capitalization (millions) | 122.62 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 5.81 |
Trailing 12 Months | 6.58 |
PEG Ratio | NA |
vs. Previous Year | -280.00% |
vs. Previous Quarter | 10.00% |
vs. Previous Year | -13.74% |
vs. Previous Quarter | 7.53% |
Price/Book | 2.53 |
Price/Cash Flow | 3.59 |
Price / Sales | 0.56 |
6/30/24 | 18.36 |
3/31/24 | 35.49 |
12/31/23 | 58.21 |
6/30/24 | 4.13 |
3/31/24 | 7.26 |
12/31/23 | 10.40 |
6/30/24 | 1.32 |
3/31/24 | 1.46 |
12/31/23 | 1.57 |
6/30/24 | 1.23 |
3/31/24 | 1.38 |
12/31/23 | 1.50 |
6/30/24 | 4.01 |
3/31/24 | 6.79 |
12/31/23 | 9.16 |
6/30/24 | 4.01 |
3/31/24 | 6.79 |
12/31/23 | 9.16 |
6/30/24 | 4.59 |
3/31/24 | 7.29 |
12/31/23 | 9.62 |
6/30/24 | 0.99 |
3/31/24 | 1.06 |
12/31/23 | 1.12 |
6/30/24 | 8.16 |
3/31/24 | 8.76 |
12/31/23 | 10.33 |
6/30/24 | 0.90 |
3/31/24 | 1.07 |
12/31/23 | 1.23 |
6/30/24 | 47.41 |
3/31/24 | 51.76 |
12/31/23 | 55.13 |